Literature DB >> 24368768

Down-regulated peroxisome proliferator-activated receptor γ (PPARγ) in lung epithelial cells promotes a PPARγ agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD).

Sowmya P Lakshmi1, Aravind T Reddy, Yingze Zhang, Frank C Sciurba, Rama K Mallampalli, Steven R Duncan, Raju C Reddy.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory condition and a leading cause of death, with no available cure. We assessed the actions in pulmonary epithelial cells of peroxisome proliferator-activated receptor γ (PPARγ), a nuclear hormone receptor with anti-inflammatory effects, whose role in COPD is largely unknown. We found that PPARγ was down-regulated in lung tissue and epithelial cells of COPD patients, via both reduced expression and phosphorylation-mediated inhibition, whereas pro-inflammatory nuclear factor-κB (NF-κB) activity was increased. Cigarette smoking is the main risk factor for COPD, and exposing airway epithelial cells to cigarette smoke extract (CSE) likewise down-regulated PPARγ and activated NF-κB. CSE also down-regulated and post-translationally inhibited the glucocorticoid receptor (GR-α) and histone deacetylase 2 (HDAC2), a corepressor important for glucocorticoid action and whose down-regulation is thought to cause glucocorticoid insensitivity in COPD. Treating epithelial cells with synthetic (rosiglitazone) or endogenous (10-nitro-oleic acid) PPARγ agonists strongly up-regulated PPARγ expression and activity, suppressed CSE-induced production and secretion of inflammatory cytokines, and reversed its activation of NF-κB by inhibiting the IκB kinase pathway and by promoting direct inhibitory binding of PPARγ to NF-κB. In contrast, PPARγ knockdown via siRNA augmented CSE-induced chemokine release and decreases in HDAC activity, suggesting a potential anti-inflammatory role of endogenous PPARγ. The results imply that down-regulation of pulmonary epithelial PPARγ by cigarette smoke promotes inflammatory pathways and diminishes glucocorticoid responsiveness, thereby contributing to COPD pathogenesis, and further suggest that PPARγ agonists may be useful for COPD treatment.

Entities:  

Keywords:  Chromatin Histone Modification; Cigarette Smoke; Glucocorticoid Receptor; Histone Deacetylase; Human Bronchial Epithelial Cells; I-kappa-B Kinase; Inflammation; NF-kappa B (NF-KB); Oxidative Stress

Mesh:

Substances:

Year:  2013        PMID: 24368768      PMCID: PMC3945305          DOI: 10.1074/jbc.M113.536805

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site.

Authors:  M Adams; M J Reginato; D Shao; M A Lazar; V K Chatterjee
Journal:  J Biol Chem       Date:  1997-02-21       Impact factor: 5.157

2.  Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12.

Authors:  K Ito; P J Barnes; I M Adcock
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

3.  The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD.

Authors:  Simon Lea; Jonathan Plumb; Hannah Metcalfe; Dianne Spicer; Paul Woodman; J Craig Fox; Dave Singh
Journal:  Eur Respir J       Date:  2013-06-21       Impact factor: 16.671

4.  Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma.

Authors:  E Hu; J B Kim; P Sarraf; B M Spiegelman
Journal:  Science       Date:  1996-12-20       Impact factor: 47.728

5.  Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway.

Authors:  I Alkalay; A Yaron; A Hatzubai; A Orian; A Ciechanover; Y Ben-Neriah
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

6.  PPARγ is an E3 ligase that induces the degradation of NFκB/p65.

Authors:  Yongzhong Hou; France Moreau; Kris Chadee
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

7.  Red cell membrane and plasma linoleic acid nitration products: synthesis, clinical identification, and quantitation.

Authors:  Paul R S Baker; Francisco J Schopfer; Scott Sweeney; Bruce A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-23       Impact factor: 11.205

8.  Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD.

Authors:  A Di Stefano; G Caramori; T Oates; A Capelli; M Lusuardi; I Gnemmi; F Ioli; K F Chung; C F Donner; P J Barnes; I M Adcock
Journal:  Eur Respir J       Date:  2002-09       Impact factor: 16.671

9.  Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration.

Authors:  K Ito; T Hanazawa; K Tomita; P J Barnes; I M Adcock
Journal:  Biochem Biophys Res Commun       Date:  2004-02-27       Impact factor: 3.575

Review 10.  Role of peroxisome proliferator-activated receptor gamma and its ligands in the control of immune responses.

Authors:  Alessio Nencioni; Sebastian Wesselborg; Peter Brossart
Journal:  Crit Rev Immunol       Date:  2003       Impact factor: 2.214

View more
  38 in total

1.  Peroxisome proliferator-activated receptor-γ agonists attenuate biofilm formation by Pseudomonas aeruginosa.

Authors:  Brahmchetna Bedi; Nicholas M Maurice; Vincent T Ciavatta; K Sabrina Lynn; Zhihong Yuan; Samuel A Molina; Myungsoo Joo; William R Tyor; Joanna B Goldberg; Michael Koval; C Michael Hart; Ruxana T Sadikot
Journal:  FASEB J       Date:  2017-04-25       Impact factor: 5.191

2.  Role of GPx3 in PPARγ-induced protection against COPD-associated oxidative stress.

Authors:  Aravind T Reddy; Sowmya P Lakshmi; Asoka Banno; Raju C Reddy
Journal:  Free Radic Biol Med       Date:  2018-08-15       Impact factor: 7.376

Review 3.  Novel approaches to the management of noneosinophilic asthma.

Authors:  Neil C Thomson
Journal:  Ther Adv Respir Dis       Date:  2016-02-28       Impact factor: 4.031

Review 4.  Inflammatory signaling and metabolic regulation by nitro-fatty acids.

Authors:  Oren Rom; Nicholas K H Khoo; Y Eugene Chen; Luis Villacorta
Journal:  Nitric Oxide       Date:  2018-03-22       Impact factor: 4.427

5.  Transforming growth factor β suppresses peroxisome proliferator-activated receptor γ expression via both SMAD binding and novel TGF-β inhibitory elements.

Authors:  Sowmya P Lakshmi; Aravind T Reddy; Raju C Reddy
Journal:  Biochem J       Date:  2017-04-24       Impact factor: 3.857

Review 6.  Epigenetic targets for novel therapies of lung diseases.

Authors:  Brian S Comer; Mariam Ba; Cherie A Singer; William T Gerthoffer
Journal:  Pharmacol Ther       Date:  2014-11-15       Impact factor: 12.310

7.  12/15-Lipoxygenase metabolites of arachidonic acid activate PPARγ: a possible neuroprotective effect in ischemic brain.

Authors:  Li Sun; Yan-Wei Xu; Jing Han; Hao Liang; Ning Wang; Yan Cheng
Journal:  J Lipid Res       Date:  2015-01-20       Impact factor: 5.922

8.  Haem oxygenase-1 up-regulation by rosiglitazone via ROS-dependent Nrf2-antioxidant response elements axis or PPARγ attenuates LPS-mediated lung inflammation.

Authors:  Rou-Ling Cho; Chien-Chung Yang; Hui-Ching Tseng; Li-Der Hsiao; Chih-Chung Lin; Chuen-Mao Yang
Journal:  Br J Pharmacol       Date:  2018-09-06       Impact factor: 8.739

9.  Clinical relevance of peroxisome proliferator-activated receptor-γ gene polymorphisms with sepsis.

Authors:  Yu Liu; Wenhui Wan; Fang Fang; Lei Guo; Yusheng Zhao; Xinghu Zhang; Fang Huang
Journal:  J Clin Lab Anal       Date:  2017-10-21       Impact factor: 2.352

10.  Effect of Pranayama on Ppar-γ, Nf-κB Expressions and Red Complex Microorganisms in Patients with Chronic Periodontitis - A Clinical Trial.

Authors:  Jaideep Mahendra; Little Mahendra; R Ananthalakshmi; Prathahini S Parthiban; Sandhya Cherukuri; Mohammed Junaid
Journal:  J Clin Diagn Res       Date:  2017-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.